Cortex Pharmaceuticals, Inc.
15Patents
7Active
15Granted
38Portfolio score
Filing activity: Mar 7, 1994 → Jan 31, 2013 · 4 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5567724A | Alkaline and acid phosphatase inhibitors in treatment of neurological disorders | Human Necessities | 105 | Expired |
| US5444042A | Method of treatment of neurodegeneration with calpain inhibitors | Human Necessities | 31 | Expired |
| US5736543A | Benzoxazines for enhancing synaptic response | Chemistry; Metallurgy | 26 | Expired |
| US8013003B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | Chemistry; Metallurgy | 20 | Active |
| US5650409A | Benzoyl piperidines/pyrrolidines for enhancing synaptic response | Chemistry; Metallurgy | 20 | Expired |
| US6166008A | Treatment of schizophrenia with ampakines and neuroleptics | Human Necessities | 14 | Expired |
| US5985871A | Benzoxazine compounds for enhancing synaptic response | Human Necessities | 3 | Expired |
| US5622981A | Use of metabotropic receptor agonists in progressive neurodegenerative diseases | Human Necessities | 3 | Expired |
| US8119632B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | Human Necessities | 1 | Active |
| US8642633B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | Chemistry; Metallurgy | 0 | Active |
| US8404682B2 | Di-substituted amides for enhancing glutamatergic synaptic responses | Chemistry; Metallurgy | 0 | Active |
| US8168632B2 | Bicyclic amide derivatives for the treatment of respiratory disorders | Human Necessities | 0 | Active |
| US8263591B2 | Bicyclic amides for enhancing glutamatergic synaptic responses | Chemistry; Metallurgy | 0 | Active |
| US8507482B2 | Bicyclic amide derivatives for enhancing glutamatergic synaptic responses | Human Necessities | 0 | Active |
| US7799913B2 | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | Chemistry; Metallurgy | 0 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.